StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research note issued to investors on Saturday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Trading Up 1.3 %
Titan Pharmaceuticals stock opened at $4.42 on Friday. The stock has a fifty day moving average price of $4.92 and a two-hundred day moving average price of $5.75. Titan Pharmaceuticals has a 52-week low of $3.57 and a 52-week high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last announced its quarterly earnings results on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) earnings per share (EPS) for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Read More
- Five stocks we like better than Titan Pharmaceuticals
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- Best Stocks Under $5.00
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- The Role Economic Reports Play in a Successful Investment Strategy
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
